Thus, changes of the cellular composition in the tumor microenvironment with a focus on CD8+PD-1+ T cells following, for example, anti-PD-1 therapy can be quantified when using multiplex methods such as Chipcytometry in future experimental setups. The gene discussed is PDCD1; the disease is neoplasm.